Compare ADMA Biologics Inc (ADMA) vs Workday Inc (WDAY) Price & Performance

ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.

The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.

Workday (WDAY) trades at $143.65, up 6.09% with strong technical momentum above key resistance at $141. The stock shows robust fundamentals with consistent earnings beats (Q1 2026 EPS of $2.66 vs. $2.51 expected) and 14.3% y/y subscription revenue growth. Recent AI product launches, including agentic AI tools with 200%+ ACV growth, position the company for continued expansion despite a recent lawsuit over AI bias in HR tools.

Outlook remains positive with 55.5% analyst buy ratings and $157.30 consensus target (9.5% upside). Key risks include the California AI bias lawsuit, competitive pressure in enterprise software, and valuation concerns at 42.99 P/E. Strong cash flow generation ($2.46B operating cash flow) supports growth investments while net cash flow turned negative due to strategic financing activities.